Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 108

1.

SIRT1 inhibition alleviates gene silencing in Fragile X mental retardation syndrome.

Biacsi R, Kumari D, Usdin K.

PLoS Genet. 2008 Mar 7;4(3):e1000017. doi: 10.1371/journal.pgen.1000017.

2.

Acetylated histones are associated with FMR1 in normal but not fragile X-syndrome cells.

Coffee B, Zhang F, Warren ST, Reines D.

Nat Genet. 1999 May;22(1):98-101. Erratum in: Nat Genet 1999 Jun;22(2):209.

PMID:
10319871
3.
4.

Histone modifications depict an aberrantly heterochromatinized FMR1 gene in fragile x syndrome.

Coffee B, Zhang F, Ceman S, Warren ST, Reines D.

Am J Hum Genet. 2002 Oct;71(4):923-32.

5.
6.

Differential epigenetic modifications in the FMR1 gene of the fragile X syndrome after reactivating pharmacological treatments.

Tabolacci E, Pietrobono R, Moscato U, Oostra BA, Chiurazzi P, Neri G.

Eur J Hum Genet. 2005 May;13(5):641-8.

7.

Histone deacetylases suppress CGG repeat-induced neurodegeneration via transcriptional silencing in models of fragile X tremor ataxia syndrome.

Todd PK, Oh SY, Krans A, Pandey UB, Di Prospero NA, Min KT, Taylor JP, Paulson HL.

PLoS Genet. 2010 Dec 9;6(12):e1001240. doi: 10.1371/journal.pgen.1001240.

8.

FMR1 CGG repeat lengths mediate different regulation of reporter gene expression in comparative transient and locus specific integration assays.

SĂžlvsten C, Nielsen AL.

Gene. 2011 Oct 15;486(1-2):15-22. doi: 10.1016/j.gene.2011.06.034.

PMID:
21767618
9.

Synergistic effect of histone hyperacetylation and DNA demethylation in the reactivation of the FMR1 gene.

Chiurazzi P, Pomponi MG, Pietrobono R, Bakker CE, Neri G, Oostra BA.

Hum Mol Genet. 1999 Nov;8(12):2317-23.

11.

Epigenetics, fragile X syndrome and transcriptional therapy.

Tabolacci E, Chiurazzi P.

Am J Med Genet A. 2013 Nov;161A(11):2797-808. doi: 10.1002/ajmg.a.36264. Review.

PMID:
24123753
12.

Quantitative analysis of DNA demethylation and transcriptional reactivation of the FMR1 gene in fragile X cells treated with 5-azadeoxycytidine.

Pietrobono R, Pomponi MG, Tabolacci E, Oostra B, Chiurazzi P, Neri G.

Nucleic Acids Res. 2002 Jul 15;30(14):3278-85.

13.

Epigenetic characterization of the FMR1 gene and aberrant neurodevelopment in human induced pluripotent stem cell models of fragile X syndrome.

Sheridan SD, Theriault KM, Reis SA, Zhou F, Madison JM, Daheron L, Loring JF, Haggarty SJ.

PLoS One. 2011;6(10):e26203. doi: 10.1371/journal.pone.0026203.

14.

Promoter-bound trinucleotide repeat mRNA drives epigenetic silencing in fragile X syndrome.

Colak D, Zaninovic N, Cohen MS, Rosenwaks Z, Yang WY, Gerhardt J, Disney MD, Jaffrey SR.

Science. 2014 Feb 28;343(6174):1002-5. doi: 10.1126/science.1245831.

15.
16.

Reversion of FMR1 Methylation and Silencing by Editing the Triplet Repeats in Fragile X iPSC-Derived Neurons.

Park CY, Halevy T, Lee DR, Sung JJ, Lee JS, Yanuka O, Benvenisty N, Kim DW.

Cell Rep. 2015 Oct 13;13(2):234-41. doi: 10.1016/j.celrep.2015.08.084.

17.

Pharmacological reactivation of inactive genes: the fragile X experience.

Chiurazzi P, Neri G.

Brain Res Bull. 2001 Oct-Nov 1;56(3-4):383-7. Review.

PMID:
11719276
18.

FMR1 epigenetic silencing commonly occurs in undifferentiated fragile X-affected embryonic stem cells.

Avitzour M, Mor-Shaked H, Yanovsky-Dagan S, Aharoni S, Altarescu G, Renbaum P, Eldar-Geva T, Schonberger O, Levy-Lahad E, Epsztejn-Litman S, Eiges R.

Stem Cell Reports. 2014 Nov 11;3(5):699-706. doi: 10.1016/j.stemcr.2014.09.001.

20.

An origin of DNA replication in the promoter region of the human fragile X mental retardation (FMR1) gene.

Gray SJ, Gerhardt J, Doerfler W, Small LE, Fanning E.

Mol Cell Biol. 2007 Jan;27(2):426-37.

Items per page

Supplemental Content

Support Center